Pharmaceutical cocrystals: The coming wave of new drug substances

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 311-317

  Brittain, Harry G ^a  

^a Center for Pharmaceutical Physics   (United States)

Author keywords

Cocrystals; Crystal engineering; Crystals; Dissolution rate; Solubility

Indexed keywords

ACETYLSALICYLIC ACID; DONEPEZIL; VALPROATE SEMISODIUM; VALPROIC ACID;

ARTICLE; CRYSTAL; CRYSTALLIZATION; DISSOLUTION; INFRARED SPECTROSCOPY; PHARMACEUTICS; SOLID STATE; X RAY POWDER DIFFRACTION;

EID: 84872433573     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23402     Document Type: Article

References (61)

1. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid state chemistry of drugs. 2nd ed. West Lafayette, Indiana: SSCI Inc.
2. Bernstein J. 2002. Polymorphism in molecular crystals. Oxford, UK: Clarendon Press.
3. Hilfiker R. 2006. Polymorphism in the pharmaceutical industry. Weinheim, Germany: Wiley-VCH.
4. Brittain HG. 2009. Polymorphism in pharmaceutical solids. 2nd ed. New York City, New York: Informa Healthcare.
5. Brittain HG. 2005. Polymorphism and solvatomorphism 2004. In Profiles of drug substances, excipients, and related methodology; Brittain HG, Ed. Vol. 32. Amsterdam, The Netherlands: Elsevier Academic Press, pp 263-283.
6. Brittain HG. 2007. Polymorphism and solvatomorphism 2005. J Pharm Sci 96:705-728.
7. Brittain HG. 2008. Polymorphism and solvatomorphism 2006. J Pharm Sci 97:3611-3636.
8. Brittain HG. 2009. Polymorphism and solvatomorphism 2007. J Pharm Sci 98:1617-1642.
9. Brittain HG. 2010. Polymorphism and solvatomorphism 2008. J Pharm Sci 99:3648-3664.
10. Brittain HG. 2011. Polymorphism and solvatomorphism 2009. J Pharm Sci 100:1260-1279.
11. Brittain HG. 2012. Polymorphism and solvatomorphism 2010. J Pharm Sci 101:464-484.
12. Kitaigorodsky AI. 1984. Mixed crystals. Berlin, Germany: Springer-Verlag.
13. Donohue J. 1952. The hydrogen bond in organic crystals. J Phys Chem 56:502-510.
14. Baur WH. 1965. On hydrogen bonds in crystalline hydrates. Acta Cryst 19:909-916.
15. Etter MC. 1990. Encoding and decoding hydrogen-bond patterns of organic compounds. Acc Chem Res 23:120-126.
16. Etter MC, MacDonald JC, Bernstein J. 1990. Graph-set analysis of hydrogen-bond patterns in organic crystals. Acta Cryst B46:256-262.
17. Etter MC. 1991. Hydrogen bonds as design elements in organic chemistry. J Phys Chem 95:4601-4610.
18. Aakeröy CB, Seddon KR. 1993. The hydrogen bond and crystal engineering. Chem Soc Rev 22:397-407.
19. Desiraju GR. 1995. Supramolecular synthons in crystal engineering-A new organic synthesis. Angew Chem Int Ed 34:2311-2327.
20. Aakeröy CB. 1997. Crystal engineering: Strategies and architectures. Acta Cryst B53:569-586.
21. Braga D, Grepioni F, Orpen AG. 1999. Crystal engineering: From molecules and crystals to materials. Dordrecht, The Netherlands: Kluwer.
22. Seddon KR, Zaworotko M. 1999. Crystal engineering: The design and application of functional solids. Dordrecht, The Netherlands: Kluwer.
23. Aakeröy CB, Champness NR, Janiak C. 2010. Recent advances in crystal engineering. CrystEngComm 12:22-43.
24. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ. 2006. Pharmaceutical cocrystals. J Pharm Sci 95:499-516.
25. Shan N, Zaworotko MJ. 2008. The role of cocrystals in pharmaceutical science. Drug Discov Today 13:440-446.
26. Schultheiss N, Newman A. 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 9:2950-2967.
27. Friščić T, Jones W. 2010. Benefits of cocrystallization in pharmaceutical materials science: An update. J Pharm Pharmacol 62:1547-1559.
28. Stahly GP. 2007. A survey of cocrystals reported prior to 2000. Cryst Growth Des 4:323-338.
29. Brittain HG. 2010. Cocrystal systems of pharmaceutical interest: 2007-2008 (chapter 9). In Profiles of drug substances, excipients, and related methodology; Brittain HG, Ed. Vol. 35. Amsterdam, The Netherlands: Elsevier Academic Press, pp. 373-390.
30. Brittain HG. 2011. Cocrystal systems of pharmaceutical interest: 2010 (chapter 10). In Profiles of drug substances, excipients, and related methodology; Brittain HG, Ed. Vol. 36., Amsterdam, The Netherlands: Elsevier Academic Press, pp. 361-381.
31. Brittain HG. 2012. Cocrystal systems of pharmaceutical interest: 2010. Cryst Growth Des 12:1046-1054.
32. Desiraju GR. 2003. Crystal and co-crystal. CrystEngComm 5:466-467.
33. Dunitz JD. 2003. Crystal and co-crystal: A second opinion. CrystEngComm 5:506-506.
34. Aakeröy C, Salmon DJ. 2005. Building co-crystals with molecular sense and supramolecular sensibility. CrystEngComm 7:439-448.
35. Bond AD. 2007. What is a co-crystal? CrystEngComm 9:833-834.
36. Aakeröy C, Fasulo ME, Desper J. 2007. Cocrystal or salt: Does it really matter? Mol Pharm 4:317-322.
37. Childs SL, Stahly GP, Park A. 2007. The salt-cocrystal continuum: The influence of crystal structure on ionization state. Mol Pharm 4:323-338.
38. Aakeröy CB, Rajbanshi A, Li ZJ, Desper J. 2010. Mapping out the synthetic landscape for recrystallization, cocrystallization, and salt formation. CrystEngComm 12:4231-4239.
39. Schultheiss N, Lorimer K, Wolfe S, Desper J. 2010. Attempted construction of minoxidil: Carboxylic acid cocrystals: 7 salts and 1 cocrystal resulted. CrystEngComm 12:742-749.
40. Mohamed S, Tocher DA, Vickers M, Karamertzanis PG, Price SL. 2009. Salt or cocrystal? A new series of crystal structures formed from simple pyridines and carboxylic acids. Cryst Growth Des 9:2881-2889.
41. Blagden N, de Matas M, Gavan PT, York P. 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Del Rev 59:617-630.
42. Good DJ, Rodríguez-Hornedo N. 2009. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des 9:2252-2264.
43. Bethune SJ, Huang N, Jayasanka A, Rodríguez-Hornedo N. 2009. Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility. Cryst Growth Des 9:3976-3988.
44. Nehm SJ, Rodríguez-Spong B, Rodríguez-Hornedo N. 2006. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst Growth Des 6:592-600.
45. Good DJ, Rodríguez-Hornedo N. 2010. Cocrystal eutectic constants and prediction of solubility behavior. Cryst Growth Des 10:1028-1032.
46. Gao Y, Zu H, Zhang J. 2011. Enhanced dissolution and stability of adefovir dipivoxil by cocrystal formation. J Pharm Pharmacol 63:483-490.
47. Shiraki K, Takata N, Takano R, Hayashi Y, Terada K. 2008. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm Res 25:2581-2592.
48. Aakeröy CB, Forbes S, Desper J. 2009. Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug. J Am Chem Soc 131:17048-17049.
49. McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, Mannion R, O'Donnell E, Park A. 2006. Pharm Res 23:1888-1897.
50. Cheney ML, Shan N, Healey ER, Hanna M, Wojtas L, Zaworotko MJ, Sava V, Song S, Sanchez-Ramos JR. 2010. Effects of crystal form on solubility and pharmacokinetics: A crystal engineering case study of lamotrigine. Cryst Growth Des 10:394-405.
51. Brittain HG, Felice PV. 2012. Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine. Patent US2010128977.
52. USP monograph for aspirin. 2011. United States Pharmacopeia, 34th ed. Rockville, Maryland: United States Pharmacopeial Convention, p 1931.
53. Center for Drug Evaluation and Research. 2011. Guidance for industry: Regulatory classification of pharmaceutical co-crystals. Rockville, Maryland: United States Food and Drug Administration.
54. Pop M, Sieger P, Cains PW. 2009. Tiotropium fumarate: An interesting pharmaceutical cocrystal. J Pharm Sci 98:1820-1834.
55. Permumalla SR, Sun CC. 2012. Design and synthesis of solid state structures with conjugate acid-base pair interactions. CrystEngComm 14:3851-3853.
56. Brittain HG. 2010. Vibrational spectroscopic studies of cocrystals and salts. 3. Cocrystal products formed by benzenecarboxylic acids and their sodium salts. Cryst Growth Des 10:1990-2003.
57. Meade EM. 1991. Sodium hydrogen divalproate oligomer. Patent US4988731.
58. Meade EM. 1993. Sodium hydrogen divalproate oligomer. Patent US5212326.
59. Brittain HG. 2012. Unpublished results for valproic acid, sodium valproate, and divalproex sodium.
60. Brittain HG. 2011. Vibrational spectroscopic studies of cocrystals and salts. 4. Cocrystal products formed by benzylamine, α-methylbenzylamine, and their chloride salts. Cryst Growth Des 11:2500-2509.
61. Brittain HG. 2012. Unpublished results for donepezil free base, donepezil hydrochloride, and the donepezil-donepezil hydrochloride salt-cocrystal.